Amakem banks €18M for ophthalmology drug studies

The Belgian biotech Amakem has raised €18 million ($25.2 million) in an impressive A round for its ophthalmology work. The biotech says it has enough money to get its lead candidate--a glaucoma drug called AMA0076--to clinical proof-of-concept. The round was led by Forbion Capital Partners and included Crédit Agricole Private Equity, Vesalius BioCapital, as well as the existing investors LRM, PMV and Life Sciences Research Partners. Release